Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/C


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
07 2019
Historique:
received: 24 12 2018
revised: 07 03 2019
accepted: 24 04 2019
pubmed: 1 5 2019
medline: 2 5 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

Glioblastoma (GBM) is the most common and lethal primary brain tumor and remains incurable. This is in part due to the cellular heterogeneity within these tumors, which includes a subpopulation of treatment-resistant cells called cancer stem-like cells (CSC). We previously identified that the anaphase-promoting complex/cylosome (APC/C), a key cell-cycle regulator and tumor suppressor, had attenuated ligase activity in CSCs. Here, we assessed the mechanism of reduced activity, as well as the efficacy of pharmacologically targeting the APC/C in CSCs. We identified hyperphosphorylation of CDH1, but not pseudosubstrate inhibition by early mitotic inhibitor 1 (EMI1), as a major mechanism driving attenuated APC/C

Identifiants

pubmed: 31036696
pii: 1541-7786.MCR-18-1361
doi: 10.1158/1541-7786.MCR-18-1361
pmc: PMC7271747
mid: NIHMS1528287
doi:

Substances chimiques

Antigens, CD 0
CDH1 protein, human 0
Cadherins 0
Carbamates 0
Cdc20 Proteins 0
Cell Cycle Proteins 0
Diamines 0
F-Box Proteins 0
FBXO5 protein, human 0
Small Molecule Libraries 0
apcin 0
CDC20 protein, human 156288-95-8
Anaphase-Promoting Complex-Cyclosome EC 2.3.2.27

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1519-1530

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM108743
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM112895
Pays : United States
Organisme : NIH HHS
ID : S10 OD023436
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Drugs R D. 2017 Jun;17(2):255-263
pubmed: 28324583
Cancer Discov. 2017 Apr;7(4):424-441
pubmed: 28174173
Nature. 2014 Oct 30;514(7524):646-9
pubmed: 25156254
Genes Dev. 2006 Sep 1;20(17):2410-20
pubmed: 16921029
Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1924-1933
pubmed: 30290241
Science. 2009 Mar 13;323(5920):1477-81
pubmed: 19286556
Cancer Res. 2011 Mar 1;71(5):1858-70
pubmed: 21363922
Nature. 2015 Jun 25;522(7557):450-454
pubmed: 26083744
Oncogene. 2010 Jan 7;29(1):1-10
pubmed: 19826416
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
Nature. 2018 Jun;558(7709):313-317
pubmed: 29875408
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046
PLoS One. 2011;6(10):e25631
pubmed: 22022424
Nat Neurosci. 2015 Apr;18(4):501-10
pubmed: 25730670
Nature. 1999 Oct 21;401(6755):815-8
pubmed: 10548110
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Cell Rep. 2014 Feb 27;6(4):670-83
pubmed: 24508461
Cancer Cell. 2010 Oct 19;18(4):382-95
pubmed: 20951947
Science. 2004 Oct 1;306(5693):117-20
pubmed: 15459393
EMBO J. 2004 Apr 7;23(7):1619-26
pubmed: 15029244
Nat Commun. 2015 Jan 06;6:5906
pubmed: 25562820
Cancer Cell. 2015 Oct 12;28(4):441-455
pubmed: 26461092
J Cell Biol. 2007 Jul 30;178(3):371-85
pubmed: 17664332
Glia. 2011 Aug;59(8):1148-54
pubmed: 21547954
Nat Cell Biol. 2008 Jul;10(7):802-11
pubmed: 18552834
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Biol Chem. 2003 Apr 4;278(14):12530-6
pubmed: 12560341
Mol Cell Biol. 2001 Aug;21(15):5071-81
pubmed: 11438663
EMBO J. 2002 Dec 2;21(23):6515-26
pubmed: 12456658
Cell. 2008 Jul 25;134(2):256-67
pubmed: 18662541
Cell Rep. 2015 Jun 23;11(11):1809-21
pubmed: 26074073
Science. 1998 Nov 27;282(5394):1721-4
pubmed: 9831566
Cell. 1994 Jul 1;77(7):1037-50
pubmed: 8020094
Oncol Rep. 2018 Aug;40(2):841-848
pubmed: 29901174
Mol Cell. 2005 Dec 22;20(6):855-66
pubmed: 16364911
Mol Biol Cell. 2016 Jul 15;27(14):2198-212
pubmed: 27226481
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cancer Discov. 2016 May;6(5):532-45
pubmed: 27001151
Ann Oncol. 2014 Sep;25 Suppl 3:iii93-101
pubmed: 24782454
J Neurooncol. 2017 May;133(1):87-95
pubmed: 28432586
Sci Transl Med. 2015 Sep 9;7(304):304ra143
pubmed: 26355032
Cancer Genet Cytogenet. 2005 Nov;163(1):44-56
pubmed: 16271955
Mol Cell. 2011 May 20;42(4):511-23
pubmed: 21596315
Cell. 2016 Jun 30;166(1):167-80
pubmed: 27368103
Sci Rep. 2015 Dec 10;5:18180
pubmed: 26658992
Oncotarget. 2015 May 30;6(15):13241-54
pubmed: 25938542
Cell Syst. 2017 Apr 26;4(4):430-444.e5
pubmed: 28330616
Cancer Discov. 2017 Feb;7(2):218-233
pubmed: 28069571
Mol Biol Cell. 2000 May;11(5):1555-69
pubmed: 10793135
J Cell Biol. 2001 Jul 9;154(1):85-94
pubmed: 11448992
Curr Biol. 1999 Mar 11;9(5):227-36
pubmed: 10074450
Nat Commun. 2014 Apr 22;5:3686
pubmed: 24751481
Oncotarget. 2016 Jan 26;7(4):4062-76
pubmed: 26716651
Virchows Arch. 2008 Dec;453(6):599-609
pubmed: 18953566

Auteurs

Kuntal De (K)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Treg M Grubb (TM)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Abigail A Zalenski (AA)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Neuroscience Graduate Program, The Ohio State University, Columbus, Ohio.

Kayla E Pfaff (KE)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio.

Debjani Pal (D)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Shubhra Majumder (S)

Department of Life Sciences, Presidency University, Kolkata, West Bengal, India.

Matthew K Summers (MK)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Monica Venere (M)

Department of Radiation Oncology, James Cancer Hospital and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. monica.venere@osumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH